Victory Capital Management Inc. boosted its position in Anika Therapeutics Inc. (NASDAQ:ANIK) by 68.4% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,452 shares of the biotechnology company’s stock after buying an additional 1,402 shares during the period. Victory Capital Management Inc.’s holdings in Anika Therapeutics were worth $150,000 at the end of the most recent reporting period.
Other institutional investors have also recently made changes to their positions in the company. Russell Investments Group Ltd. purchased a new position in shares of Anika Therapeutics during the fourth quarter worth approximately $5,532,000. Comerica Bank increased its position in shares of Anika Therapeutics by 4.9% in the fourth quarter. Comerica Bank now owns 15,834 shares of the biotechnology company’s stock worth $792,000 after buying an additional 739 shares in the last quarter. State Street Corp increased its position in shares of Anika Therapeutics by 3.2% in the fourth quarter. State Street Corp now owns 316,791 shares of the biotechnology company’s stock worth $15,507,000 after buying an additional 9,917 shares in the last quarter. FMR LLC purchased a new position in shares of Anika Therapeutics during the fourth quarter worth approximately $1,772,000. Finally, Allianz Asset Management AG increased its position in shares of Anika Therapeutics by 7.0% in the fourth quarter. Allianz Asset Management AG now owns 38,117 shares of the biotechnology company’s stock worth $1,867,000 after buying an additional 2,489 shares in the last quarter. Institutional investors and hedge funds own 80.80% of the company’s stock.
Shares of Anika Therapeutics Inc. (NASDAQ:ANIK) traded down 2.77% during midday trading on Friday, hitting $50.27. The stock had a trading volume of 118,104 shares. The firm has a 50 day moving average price of $47.90 and a 200 day moving average price of $46.92. Anika Therapeutics Inc. has a one year low of $41.38 and a one year high of $53.50. The stock has a market cap of $736.81 million, a PE ratio of 22.33 and a beta of 1.69.
Anika Therapeutics (NASDAQ:ANIK) last issued its earnings results on Wednesday, July 26th. The biotechnology company reported $0.76 earnings per share for the quarter, topping the consensus estimate of $0.44 by $0.32. Anika Therapeutics had a return on equity of 14.88% and a net margin of 30.44%. The business had revenue of $33.50 million for the quarter, compared to analyst estimates of $27.20 million. During the same quarter last year, the company earned $0.57 EPS. The business’s quarterly revenue was up 25.9% on a year-over-year basis. On average, equities analysts forecast that Anika Therapeutics Inc. will post $1.91 earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Victory Capital Management Inc. Has $150,000 Position in Anika Therapeutics Inc. (NASDAQ:ANIK)” was published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be accessed at https://www.chaffeybreeze.com/2017/07/29/victory-capital-management-inc-raises-stake-in-anika-therapeutics-inc-nasdaqanik-updated-updated-updated.html.
Separately, Zacks Investment Research downgraded shares of Anika Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, May 8th.
In other Anika Therapeutics news, CEO Charles H. Sherwood sold 14,201 shares of Anika Therapeutics stock in a transaction that occurred on Wednesday, July 5th. The stock was sold at an average price of $50.03, for a total value of $710,476.03. Following the transaction, the chief executive officer now directly owns 246,740 shares in the company, valued at approximately $12,344,402.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Jeffery S. Thompson sold 10,725 shares of Anika Therapeutics stock in a transaction that occurred on Monday, May 22nd. The shares were sold at an average price of $47.39, for a total value of $508,257.75. Following the completion of the transaction, the director now owns 15,845 shares in the company, valued at $750,894.55. The disclosure for this sale can be found here. 6.57% of the stock is currently owned by company insiders.
Anika Therapeutics Company Profile
Anika Therapeutics, Inc is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration.
Receive News & Ratings for Anika Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.